Access our support and expertise:
The National Medicines Safety Improvement Programme (MedSIP) is part of the National Patient Safety Strategy.
The programme aims to address the most important causes of severe harm associated with medicines, that continue to challenge the health and care systems in England.
A new programme that launched in in April 2025 will focus on helping people with a learning disability, who have behaviour that challenges, to avoid harm from psychotropic medicines.
Behaviour that challenges is not a diagnosis, it describes a range of behaviour that some people with learning disability may display when their needs are not being met.
Learn more about the programme by expanding the sections below.
For queries related to our medicines work, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
In addition to our local delivery role, Health Innovation East Midlands and Health Innovation West Midlands were jointly commissioned as lead Patient Safety Collaboratives (PSCs) by NHS England to coordinate and support delivery of MedSIP nationally across all 15 PSCs. In Year 2 of the programme, we worked collaboratively with NHS England and system partners to build national learning infrastructure, develop data and measurement tools, and drive whole-system improvement. The overview below highlights what we delivered together, and the impact achieved.
Where possible, psychotropic medicines should be avoided for behaviour that challenges. But when needed, prescribing should be at the lowest dose, be reviewed regularly, and stopped as soon as possible.
There are about 1.3 million people with a learning disability in England(1). Approximately 14% of people with a learning disability are prescribed antipsychotic medicines compared to 1% of people without a learning disability.
Psychotropic medications include antipsychotics, antidepressants, anxiolytics (benzodiazepines), anti-seizure medication (antiepileptics), sedatives (including hypnotics) and stimulants. They affect the working of the brain and impact on a person’s mood, thoughts, perceptions and behaviour. These medications can often have side-effects and can also affect a person’s quality of life, so should only be used if there is a clear clinical indication.
We aim to support selected Integrated Care Systems across England to take a systems approach to change that brings together NHS providers, social care, voluntary sector and lived experience.
We have estimated the possible harms that could be avoided from this work as:
*e.g. Positive Behavioural Support (PBS), sensory integration, social prescribing and psychological approaches including mindfulness and lifestyle interventions.
For more information please email This email address is being protected from spambots. You need JavaScript enabled to view it.